Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. (symbol: PSNL) is a leading genome-scale diagnostics company dedicated to advancing the field of genome-guided medicine. The company's mission is to extract the most accurate genetic data from each sample and draw reliable, medically-focused conclusions. Personalis leverages cutting-edge whole genome and exome sequencing techniques, conducted in their state-of-the-art laboratory, to provide comprehensive insights.
Personalis offers a range of products and services designed to support academic, pharmaceutical, and biotech researchers. Their flagship products include ImmunoID NeXT, NeXT Personal, and NeXT Dx Test, which cater to diverse needs including personalized cancer vaccines and next-generation cancer immunotherapies. Additionally, their solutions serve those engaged in large case-control and family-based genome studies of complex or Mendelian diseases, pharmacogenomics, and cancer research.
Their proprietary databases, advanced human reference sequences, and sophisticated algorithms ensure accurate and comprehensive end-to-end human genome sequencing and analysis. Personalis' commitment to quality and innovation positions them as a critical player in the evolving landscape of genomic medicine.
Recent achievements include partnerships with key pharmaceutical companies to enhance the development of personalized cancer treatments. The company continues to innovate and expand its service offerings, ensuring researchers and clinicians have access to the most advanced tools for genomic analysis.
For those seeking the latest updates and relevant information on Personalis, Inc., StockTitan provides a comprehensive list of news and developments, ensuring investors and stakeholders stay informed on this pioneering company's performance and advancements.
Personalis, Inc. (Nasdaq: PSNL) announced its participation in upcoming investor conferences to showcase its advancements in cancer genomics. The company will present at the Bank of America 2022 Healthcare Conference on May 11, 2022, at 6:20 p.m. ET in Las Vegas, and at the UBS Global Healthcare Conference on May 24, 2022, at 3:30 p.m. ET in New York. Personalis is committed to enhancing precision cancer therapies through its innovative NeXT Platform, which evaluates nearly 20,000 human genes from a single sample.
Evaxion Biotech and Personalis announced a collaboration utilizing the ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy of Evaxion's cancer immunotherapy EVX-01. The trial will study the combination of EVX-01 with KEYTRUDA in metastatic melanoma patients. Evaxion's AI tool PIONEER is expected to enhance treatment precision by targeting significant cancer mutations. The partnership aims to improve patient outcomes and advance companion diagnostics. Both companies leverage advanced AI and genomic technologies to boost cancer therapy development.
Personalis, Inc. (Nasdaq: PSNL) announced the appointment of James Azzaro as the Vice President of Diagnostic Sales, a new role aimed at enhancing the company's clinical market presence. With over 20 years in oncology diagnostics, Azzaro is set to lead efforts to grow clinical test volumes and secure reimbursement for the NeXT Dx™ and NeXT Personal™ tests. CEO John West expressed confidence in Azzaro's ability to drive commercial success in partnering with healthcare systems and oncologists across the United States.
Personalis, Inc. (NASDAQ: PSNL) will release its Q1 2022 financial results on May 4, 2022, at 2:00 p.m. PT. Following the release, a conference call will occur to discuss financial results and highlights. Interested participants can join via phone or through a live webcast on the company's website.
Personalis specializes in advanced genomics for cancer treatments, utilizing the Personalis NeXT Platform to provide comprehensive genetic insights from single samples, enhancing precision cancer therapies.
Personalis, Inc. (NASDAQ: PSNL) has published a study in Nature Communications detailing the development of DASH, a machine learning-based algorithm for detecting human leukocyte antigen loss of heterozygosity (HLA LOH). This biomarker is crucial for cancer immunotherapy and helps cancer cells evade immune detection. The study showed DASH's increased sensitivity in identifying HLA LOH across various tumor types among 610 patients, with notable prevalence in non-small cell lung cancer (24%), cervical cancer (38%), and head and neck cancers (40%).
Personalis, Inc. (NASDAQ: PSNL) announced the issuance of US Patent No. 11,299,783 on April 12, 2022, concerning its NeXT Personal minimal residual disease (MRD) detection platform. This patent covers innovative methods for a personalized assay, enhancing tumor burden measurement and tracking of tumor variants. The NeXT Personal platform uniquely integrates detection and characterization of tumors, positioning it as a potential new standard in cancer monitoring. Personalis now holds 19 patents in genomic sequencing and analysis, with over 25 additional applications pending.
Personalis, Inc. (NASDAQ: PSNL) announced a collaborative study with Merck KGaA, presented at the American Association for Cancer Research Annual Meeting 2022 from April 8-13. This study utilizes advanced transcriptome and exome data to enhance colorectal cancer molecular subtyping. The research aims to integrate mutation profiles for better subtype identification in late-stage CRC. Richard Chen, MD, emphasized the potential of this collaboration in advancing cancer diagnostics and treatment strategies.
Personalis, Inc. (NASDAQ: PSNL), a leader in cancer genomics, announced its participation at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 2:15 p.m. Eastern Time. This event highlights the company's innovation in precision cancer therapies and diagnostics through its Personalis NeXT Platform®, which analyzes all human genes and the immune system from a single sample. Personalis is committed to advancing cancer sequencing with a focus on clinical accuracy, quality, and efficiency.
Personalis, Inc. (Nasdaq: PSNL) has appointed Karin Eastham as the new Board Chair, effective May 17, 2022. Eastham, who joined the Board in 2019, has a notable history with Illumina and Veracyte, contributing to substantial growth in both organizations. Her leadership is expected to enhance the company’s oncology diagnostics business, leveraging advanced technologies already generating rapid revenue growth from pharmaceutical partnerships. Former Chair Jonathan MacQuitty will not seek re-election but will continue as a strategic advisor.
Personalis, Inc. (Nasdaq: PSNL) announced its participation at the AACR Annual Meeting 2022, presenting five scientific posters from April 8-13, 2022. The company aims to showcase advances in precision oncology with a focus on genomic data and innovative techniques like the NeXT Liquid Biopsy and ImmunoID NeXT Platform. These studies highlight the ability to monitor somatic mutations in cancer patients and assess immune cell compositions, enhancing understanding of tumor biology and treatment resistance.
FAQ
What is the current stock price of Personalis (PSNL)?
What is the market cap of Personalis (PSNL)?
What does Personalis, Inc. specialize in?
What are Personalis' main products?
Who can benefit from Personalis' services?
What technologies does Personalis use?
What is the mission of Personalis, Inc.?
How does Personalis support cancer research?
What recent achievements has Personalis made?
What sets Personalis apart from other genomic companies?
Why is genome sequencing important in medical research?
How can I stay updated on Personalis' latest news?
